Effect of Agmatine on Non-Alcoholic Fatty Liver Disease Induced by Type 2 Diabetes in Rats
Journal of Pharmaceutical Research International,
Aim: To determine the potential hepatoprotective effect of Agmatine (AGM) on NAFLD-induced by Type 2 diabetes mellitus (T2DM) in rats.
Study design: Forty male Wistar rats weighing from (200 -250 g) were distributed at random into five groups (8 rats per group): group 1 as control; group 2 as untreated-T2DM; groups 3 & 4 as T2DM cotreated with AGM (40 & 80 mg/kg/d), while group 5 T2DM cotreated with Silymarin (100 mg/kg/d).
Place and duration of study: Department of Pharmacology, Faculty of Medicine, king Abdul-Aziz University; between October 2020 and January 2021.
Methodology: A rat model of T2DM with NAFLD complication was established by feeding rats with 10% fructose in drinking water and intraperitoneally injecting them with a single low dose of streptozotocin (STZ) (45mg/kg). The fasting blood glucose was detected, serum levels of hepatic biomarkers were all assessed. Moreover, histopathological examination was performed by hematoxylin and eosin (H&E) staining.
Results: STZ induced T2DM in rats causes a significant (p<0.05, n=8) rise in serum levels of FBG, ALT, AST, TB, TC, TG, and LDL in comparison with the corresponding control group. Co-treatment with AGM (40 & 80 mg/kg) and silymarin significantly alleviated hyperglycemia and amended hepatic biomarkers that was reflected on improved histopathological changes.
Conclusion: The current data suggest that oral AGM co-treatment could have a hepatoprotective effect against T2DM associated with NAFLD in rats. Further investigations are recommended to elucidate molecular mechanisms accountable for the useful effects of AGM on hepatocytes.
- NAFLD and T2DM disease
How to Cite
Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View. Clinics in Liver Disease. 2018;22(1):11-21.
Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non‐alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabetic Medicine. 2017;34(4):505-13.
Xia M-F, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Frontiers in Pharmacology. 2019;10(877).
Xu X, Wang W, Lin L, Chen P. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats. Tissue and Cell. 2020;66:101382.
Wang K, Tan W, Liu X, Deng L, Huang L, Wang X, et al. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. Biomedicine & Pharmacotherapy. 2021;137:111326.
Akman Ö, Utkan T, Arıcıoğlu F, Güllü K, Ateş N, Karson A. Agmatine has beneficial effect on harmaline-induced essential tremor in rat. Neuroscience Letters. 2021;753:135881.
Molderings G, Heinen A, Menzel S, Lübbecke F, Homann J, Göthert M. Gastrointestinal uptake of agmatine: distribution in tissues and organs and pathophysiologic relevance. Annals of the New York Academy of Sciences. 2004;1009:44-51.
Bergin DH, Jing Y, Williams G, Mockett BG, Zhang H, Abraham WC, et al. Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate. Scientific Reports. 2019;9(1):12669.
Gilad G, Gilad V. Long-Term (5 Years), High Daily Dosage of Dietary Agmatine—Evidence of Safety: A Case Report. Journal of medicinal food. 2014;17.
Gilad GM, Gilad VH. Evidence for oral agmatine sulfate safety – A 95-day high dosage pilot study with rats. Food and Chemical Toxicology. 2013;62:758- 62.
Kotagale N, Rahmatkar S, Chauragade S, Dixit M, Umekar M, Chopde C, et al. Involvement of hippocampal agmatine in β1-42 amyloid induced memory impairment, neuroinflammation and BDNF signaling disruption in mice. NeuroToxicology. 2020;80:1-11.
Piletz JE, Aricioglu F, Cheng J-T, Fairbanks CA, Gilad VH, Haenisch B, et al. Agmatine: clinical applications after 100 years in translation. Drug Discovery Today. 2013;18(17):880-93.
Dixit M, Upadhya M, Taksande B, Raut P, Umekar M, Kotagale N. Neuroprotective effect of agmatine in mouse spinal cord injury model: Modulation by imidazoline receptors. Journal of Natural Science, Biology and Medicine. 2018;9(2):115-20.
Kang S, Kim C-H, Jung H, Kim E, Song H-T, Lee JE. Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling. Neuropharmacology. 2017;113:467-79.
Sharawy M, El-Awady M, Megahed N, Gameil N. Attenuation of insulin resistance in rats by agmatine: role of SREBP-1c, mTOR and GLUT-2. Naunyn-Schmiedeberg's archives of pharmacology. 2016;389.
Dejanovic B, Stevanovic I, Ninkovic M, Stojanovic I, Vukovic-Dejanovic V. Protective effect of agmatine in acute chlorpromazine hepatotoxicity in rats. Acta Veterinaria Brno. 2014;83:305-12.
Samy DM, Hassan PS, Ismail CA, Hady MA, Eshra MA. Agmatine inhibits nuclear factor-κB nuclear translocation in acute spinal cord compression injury rat model. Alexandria Journal of Medicine. 2016;52(3):251-60.
Goboza M, Aboua Y, Chegou N, Oguntibeju O. Vindoline effectively ameliorated diabetes-induced hepatotoxicity by docking oxidative stress, inflammation and hypertriglyceridemia in type 2 diabetes-induced male Wistar rats. Biomedicine & Pharmacotherapy. 2019;22:1-9.
Shannon R, Islam M. Fructose-fed streptozotocin-injected rat: An alternative model for type 2 diabetes. Pharmacological reports: PR. 2012;64:129-39.
Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. Sultan Qaboos Univ Med J. 2016;16(2):e132-e41.
Bagul PK, Middela H, Matapally S, Padiya R, Bastia T, Madhusudana K, et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacological Research. 2012; 66(3):260-8.
Naidu PB, Ponmurugan P, Begum MS, Mohan K, Meriga B, RavindarNaik R, et al. Diosgenin reorganises hyperglycaemia and distorted tissue lipid profile in high‐fat diet–streptozotocin‐induced diabetic rats. J Sci Food Agric. 2015;95(15):3177-82.
Bila I, Dzydzan O, Brodyak I, Sybirna N. Agmatine prevents oxidative-nitrative stress in blood leukocytes under streptozotocin-induced diabetes mellitus. Open Life Sciences. 2019;14(1):299-310.
Flannery C, Dufour S, Rabøl R, Shulman GI, Petersen KF. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes. 2012;61(11):2711-7.
El-Awady MS, Suddek GM. Agmatine ameliorates atherosclerosis progression and endothelial dysfunction in high cholesterol-fed rabbits. Journal of Pharmacy and Pharmacology. 2014;66(6):835-43.
Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. Archives of Medical Research. 2021;52(1):25-37.
Abstract View: 0 times
PDF Download: 0 times